AstraZeneca has lifted the veil on the large-scale THALES trial of its antiplatelet drug Brilinta in stroke, the company’s last big hope for recouping its substantial investment in the medicine.

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

The goal of DrugSorb-ATR, an investigational medical device, is to reduce the severity of perioperative bleeding in patients on ticagrelor (Brilinta®, AstraZeneca) undergoing coronary artery ...

Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...

The heparin frequently given before percutaneous coronary intervention (PCI) should be pushed to as early as possible in ...

CytoSorbents (CTSO) announced the U.S. Food and Drug Administration, FDA, has accepted its De Novo medical device application for DrugSorb-ATR ...

Greenwashing allegations against Santos could pave the way for increased litigation over corporate net-zero plans if the ...

St James's Place is growing faster than the industry after jumping through regulatory hoops – and the share ...

Dakota Wealth Management cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.8% in the 3rd quarter, ...

US FDA ASSIGNS NEW PDUFA DATE FOR BRILINTA (TICAGRELOR TABLETS) AstraZeneca announced today that the US Food and Drug Administration (FDA) has acknowledged receipt of the company's reply to the ...

AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 37,100 shares ...

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...